Skip to main content

immunotherapy

Research in Review
06/27/2017
JCP Editors
An immunotherapy agent drastically improved patient-reported quality of life (QoL) in short and long-term analyses compared with conventional chemotherapy for patients with head and neck cancer, according to research...
An immunotherapy agent drastically improved patient-reported quality of life (QoL) in short and long-term analyses compared with conventional chemotherapy for patients with head and neck cancer, according to research...
An...
06/27/2017
Journal of Clinical Pathways
Research in Review
06/20/2017
JCP Editors
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research...
Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research...
Women...
06/20/2017
Journal of Clinical Pathways
Research in Review
06/13/2017
JCP Editors
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
Multiple studies have demonstrated positive results for chimeric antigen receptor (CAR) T-cells in treating relapsed and refractory multiple myeloma, according to presentations at the 2017 ASCO Annual Meeting (June...
...
06/13/2017
Journal of Clinical Pathways
Research in Review
06/01/2017
JCP Editors
A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...
A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...
A...
06/01/2017
Journal of Clinical Pathways
Research in Review
05/30/2017
JCP Editors
Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...
Patients with advanced non-small cell lung cancer (NSCLC) who receive previous radiotherapy are more likely to benefit from immunotherapy than those patients without previous radiotherapy, according to research...
...
05/30/2017
Journal of Clinical Pathways
Research in Review
05/15/2017
JCP Editors
Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...
Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...
...
05/15/2017
Journal of Clinical Pathways
Research in Review
05/03/2017
JCP Editors
Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the...
Patients with lung cancer who are treated with immunotherapy may be at increased risk of severe adverse events after receiving the seasonal influenza vaccination, according to results of a study presented at the...
...
05/03/2017
Journal of Clinical Pathways
Interview
04/12/2017
JCP Editors
The future of clinical pathways largely depends on alternative payment models such as the Oncology Care Model sponsored by CMS, according to Edward Stepanski, PhD. ----- What inspired you to work in oncology? My...
The future of clinical pathways largely depends on alternative payment models such as the Oncology Care Model sponsored by CMS, according to Edward Stepanski, PhD. ----- What inspired you to work in oncology? My...
The...
04/12/2017
Journal of Clinical Pathways
Department
04/12/2017
JCP Editors
Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors,...
Recent research suggests a particular immunotherapy may be less costly and offer time savings compared with nivolumab for patients with metastatic non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors,...
Recent...
04/12/2017
Journal of Clinical Pathways
Interview
03/23/2017
JCP Editors
Journal of Clinical Pathways spoke with Peter Martin, MD, Lymphoma Service Chief, Weill Cornell Medicine and New York-Presbyterian, about the role of targeted therapies and clinical pathways in...
Journal of Clinical Pathways spoke with Peter Martin, MD, Lymphoma Service Chief, Weill Cornell Medicine and New York-Presbyterian, about the role of targeted therapies and clinical pathways in...
...
03/23/2017
Journal of Clinical Pathways